GLP-1 Eligibility 2026: Who Qualifies for Wegovy and Zepbound, and Why Insurance Says No Anyway
There are three different eligibility bars and they do not agree: what the FDA label says, what your insurer requires, and what a telehealth questionnaire will approve. Understanding which one you are being measured against explains almost every confusing answer you will get.
By Med Consumer Watch Team
"Do I qualify?" has three different answers depending on who is asking, and almost all the confusion in this area comes from not knowing which one you are dealing with.
The FDA's criteria determine what the drug is approved to treat. Your insurer's criteria determine whether someone else pays. A telehealth provider's criteria determine whether they will write you a prescription. These three bars sit at different heights, and the middle one is usually the highest.
The FDA criteria for Wegovy and Zepbound are:
- BMI of 30 or above — obesity, on BMI alone, no additional diagnosis required, or
- BMI of 27 to 29.9 — overweight, plus at least one weight-related condition
That is the standard the approval rests on. Your insurance will frequently require more, and a telehealth questionnaire will frequently require less.
This page covers all three, plus the group that matters most: the people who should not take these medications at all, regardless of BMI.
The FDA Standard
This is the baseline — what the medication is approved for.
BMI 30 or above: you meet the weight criterion on BMI alone. No comorbidity is required.
BMI 27 to 29.9: you meet it only with at least one weight-related comorbidity. The conditions that count include:
Hypertension (high blood pressure)
Type 2 diabetes
Dyslipidaemia (abnormal cholesterol or triglycerides)
Obstructive sleep apnoea
Established cardiovascular disease
Calculate your BMI honestly and from current measurements. Telehealth intake forms are self-reported, and there is an obvious temptation to adjust a number by a few pounds or an inch of height to clear a threshold. That is a bad idea for a reason that has nothing to do with rule-following: the clinician's assessment of whether this drug is appropriate for you — and at what dose — rests on the information you give them. A prescription obtained on inaccurate data is a prescription written for someone who does not exist.
BMI is a crude instrument and clinicians know it. It does not distinguish muscle from fat, and it performs differently across ethnic groups — several guidelines apply lower thresholds for people of South Asian, Chinese and some other ancestries, because cardiometabolic risk appears at lower BMI. If your BMI sits just under a threshold, that is a conversation to have with a clinician rather than a closed door. Waist circumference, body composition and your actual metabolic markers are all relevant.
Why Insurance Says No Anyway
Meeting the FDA criteria does not mean your plan will pay. Insurers apply their own utilisation-management rules on top, and they are typically stricter.
Common additional requirements:
- A higher BMI threshold than the FDA's — 35 or 40 rather than 30
- Documented failure of prior treatment — often a supervised diet and exercise programme of specified duration
- Additional or specific comorbidities beyond the FDA's list
- Prior authorisation, with clinical documentation submitted and reviewed before approval
- Step therapy — trying and failing a cheaper medication first
- Exclusion of weight-loss indications entirely — many plans cover GLP-1s for type 2 diabetes but not for obesity
That last one is the most common and the most frustrating. It is why people are told their plan "covers Ozempic but not Wegovy" — the same molecule, approved for two indications, covered for one.
This is also why coverage varies so wildly between people who look similar on paper. It is not your BMI that differs; it is your employer's plan design.
If you have type 2 diabetes, the picture changes substantially — GLP-1 coverage for diabetes is far more common than for obesity. That is a reason to be precise with your prescriber about your actual diagnoses rather than framing the conversation purely around weight.
Two things worth doing before you assume you are not covered. First, call the number on your card and ask specifically: "Does my plan cover GLP-1 receptor agonists for weight management, and what is required for prior authorisation?" Ask for the criteria in writing. Second, if the answer is no, ask whether an appeal or a formulary exception is available — appeals succeed more often than people expect, particularly with documented comorbidities. Our insurance and HSA/FSA guide covers the process in more detail.
The Telehealth Bar Is Lower, and That Cuts Both Ways
Cash-pay telehealth providers are not bound by your insurer's utilisation rules, because nobody is being asked to reimburse. Their eligibility assessment is a clinical one made by the prescribing clinician — and in practice, the depth of that assessment varies enormously.
Across the providers we have reviewed, intake ranges from a three-minute questionnaire with no video visit at one end to required monthly follow-up visits for six months at the other. Both are legal. They are not equivalent.
The advantage of the lower bar is real. People who genuinely meet FDA criteria but whose employer excluded weight-loss drugs from the formulary are not clinically ineligible — they are commercially excluded. Cash-pay telehealth is a legitimate route for them.
The risk is also real. A questionnaire cannot ask a follow-up question. If your answer to "any history of pancreatitis?" is ambiguous, a form moves on and a clinician does not.
Ask before choosing a provider: will I speak to a clinician, or is this a form?
If your history is complex — pancreatitis, gallbladder disease, thyroid nodules, diabetic retinopathy, eating disorder history, multiple medications — choose a provider that conducts a real consultation
If your history is straightforward and you meet FDA criteria clearly, a questionnaire-based provider is a reasonable route
Either way, answer honestly. The screening exists to catch the things that make this medication dangerous for a minority of people
One eligibility question no questionnaire will ask you: whether you actually want to be on a chronic medication. GLP-1s are not a course of treatment with an endpoint. Trial evidence runs 68 to 72 weeks and weight regain after stopping is well documented. Being eligible is not the same as being ready, and it is a fair thing to think about before starting rather than after.
Who Should Not Take These Medications
This is the most important section on the page, and it applies regardless of BMI, insurance or provider.
Absolute contraindications — do not take a GLP-1 if you have:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Both semaglutide and tirzepatide carry a boxed warning — the FDA's most serious — regarding thyroid C-cell tumours observed in rodent studies. Whether this translates to humans is not established, but the contraindication is not optional.
Also excluded or requiring specific caution:
- Pregnancy, planning pregnancy, or breastfeeding. These medications are not for use in pregnancy, and effective contraception matters — weight loss can restore fertility in people who were not previously ovulating regularly
- Prior serious hypersensitivity to semaglutide, tirzepatide or any excipient
- History of pancreatitis — requires careful discussion
- Gallbladder disease — rapid weight loss increases gallstone risk
- Severe gastrointestinal disease or gastroparesis — these drugs slow gastric emptying by design
- Diabetic retinopathy — rapid glycaemic improvement has been associated with transient worsening
- A history of eating disorders — requires specialist input, not a questionnaire
- Type 1 diabetes — these are not a substitute for insulin
Tell your prescriber every medication you take, not just the obvious ones. GLP-1s slow gastric emptying, which changes how and when other oral medications are absorbed — this matters particularly for oral contraceptives, thyroid medication and anything with a narrow therapeutic window. If you take insulin or a sulfonylurea, doses frequently need reducing to avoid hypoglycaemia. This is not a drug to add on top of an existing regimen without review.
If you are on a GLP-1 and experience severe abdominal pain that radiates to your back, particularly with vomiting, seek medical attention — that is the presentation of pancreatitis and it is one of the reasons the screening questions exist. Sudden vision changes also warrant same-day assessment.
Frequently Asked Questions
What BMI do I need for Wegovy or Zepbound?BMI 30 or above on weight alone, or BMI 27–29.9 with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or established cardiovascular disease.
I meet the FDA criteria but my insurance refused. Why?
Insurers apply their own rules on top of FDA approval — commonly a higher BMI threshold, documented prior treatment failure, prior authorisation, step therapy, or an outright exclusion of weight-loss indications. Many plans cover GLP-1s for diabetes but not obesity.
My plan covers Ozempic but not Wegovy. How?
Same molecule, different approved indication. Ozempic is approved for type 2 diabetes and Wegovy for weight management, and many formularies cover the former and exclude the latter.
Can I get a prescription if my BMI is 26?
Not under the FDA criteria for these drugs. If your BMI sits just below a threshold, discuss it with a clinician — waist circumference, body composition and metabolic markers all matter, and some guidelines apply lower BMI thresholds for certain ethnic groups.
Will a telehealth provider approve me if my insurance won't?
Often, yes — cash-pay providers are not bound by your insurer's utilisation rules. That is legitimate for people who are clinically appropriate but commercially excluded. It is not a reason to misreport your history.
Who absolutely cannot take these drugs?
Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Both carry a boxed warning about thyroid C-cell tumours in rodents. Also excluded or requiring specialist input: pregnancy or planning pregnancy, prior serious hypersensitivity, and — with careful discussion — pancreatitis history, gallbladder disease, gastroparesis, diabetic retinopathy, eating disorder history and type 1 diabetes.
Do I need labs first?
Requirements vary by provider. Baseline labs are good practice and some providers require them; questionnaire-based providers frequently do not. If you have not had recent bloodwork, getting it is sensible regardless of whether it is mandatory.
Does being eligible mean I should start?
No. These are chronic treatments — trial evidence runs 68 to 72 weeks and weight regain after stopping is well documented. Eligibility is a clinical threshold, not a recommendation.
Can I take a GLP-1 with my other medications?
Tell your prescriber everything you take. These drugs slow gastric emptying and change absorption of oral medications, and insulin or sulfonylurea doses often need reducing to avoid hypoglycaemia.
The Bottom Line
There are three eligibility bars and they are set at different heights.The FDA's is the clinical baseline: BMI 30 or above, or BMI 27–29.9 with at least one weight-related condition — hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or established cardiovascular disease.
Your insurer's is usually higher, and it is where most people actually get stopped: higher BMI thresholds, documented prior treatment failure, prior authorisation, step therapy, or a blanket exclusion of weight-loss indications. This is a plan-design question, not a medical one — which is why two people with identical health can get opposite answers.
A telehealth provider's is usually lower, because nobody is being asked to reimburse. For someone clinically appropriate but commercially excluded, that is a legitimate route. The caution is that intake depth varies from a three-minute form to required monthly visits, and a form cannot ask a follow-up question.
The bar that matters most is none of those three. Regardless of BMI, insurance or provider, do not take these medications if you have a personal or family history of medullary thyroid carcinoma or MEN 2 — both drugs carry a boxed warning. Pregnancy, prior serious hypersensitivity, pancreatitis history, gallbladder disease, gastroparesis, diabetic retinopathy and eating disorder history all require a real clinical conversation rather than a checkbox.
Two practical steps. Call your insurer and ask, in these words, whether your plan covers GLP-1 receptor agonists for weight management and what prior authorisation requires — get it in writing, and ask about appeals if the answer is no. And whichever route you take, answer the screening questions accurately. They are short, they are easy to shade, and they exist to catch the small number of people for whom this medication is genuinely dangerous.
We are not healthcare professionals and this is not medical advice. Eligibility for any prescription medication is a determination for a licensed clinician who knows your full history. Semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Seek medical attention for severe abdominal pain radiating to the back, or for sudden vision changes. This is an affiliate marketing website; see our [disclosure](/disclosure).
This article is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making decisions about your health or medications. Individual experiences may vary.
Enter for a chance to use it toward eligible CoreAge Rx products and services.
The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.
